Why the study?
Does growth hormone therapy cause clinically significant metabolic side-effects in children with growth disorders?
Does growth hormone therapy cause clinically significant metabolic side-effects in children with growth disorders?
Growth hormone therapy in children appears metabolically safe over 5 years, causing only physiological increases in insulin resistance similar to normal puberty.
Supports metabolic safety of growth hormone over 5 years in children; leaves open need for prospective randomized confirmation.
No metabolic side-effects of clinical significance have been reported during a 5-year study of growth hormone (GH) therapy in children with GH deficiency, Turner syndrome, idiopathic short stature or chronic renal insufficiency. In particular, insulin levels increase but remain within the normal range, as do glucose and haemoglobin A(1c). A recent study showed that the effects of growth on insulin sensitivity in prepubertal children with idiopathic short stature represent the changes in carbohydrate tolerance observed during normal adolescence. Thus, GH treatment may lead to prolongation of the physiological state of insulin resistance observed in normal puberty. Insulin levels during the fasting state and 2 h after a standard glucose load showed no further rise after the first 3 years of continuous GH therapy. The hyperinsulinaemia observed during GH therapy may, therefore, amplify the anabolic effects of insulin on protein metabolism during puberty.
No takes yet. Share an insight, caveat, or question.
Paul Saenger (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: